Stock Chart
RPRX
Type: SELL growth_1yr
Strike: $48
Premium: $2.60
Expiry: Dec 18, 2026
Target: $46
Score: -100
LEAPs are long-term options (1+ year) with less time decay.
Vol: Current volume vs 20-day average
vs SPY: Relative activity vs market
vs QQQ: Relative activity vs tech
Color Guide:
● Red (≥1.5x): High activity
● Yellow (≥1.2x): Above average
● Blue (≤0.7x): Low activity
Interpretation:
• vs SPY > 1: Stock-specific interest
• vs SPY < 1: Stock quiet vs market
Technical Chart
About RPRX - Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Key Statistics
More RPRX Analysis
This RPRX stock chart provides comprehensive technical analysis including candlestick patterns, volume profile analysis, and options open interest data. Track RPRX's price movements with trendlines, gamma walls, and key support/resistance levels.